Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. due to allegations of misleading practices related to Medicare insurance plans, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by October 10, 2025 [4][6]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that compensated the company best, regardless of quality [6]. - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage plans and received illegal kickbacks from insurers [6]. - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to 2021, leading to a significant drop in stock price [7]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased SelectQuote securities between September 9, 2020, and May 1, 2025, are encouraged to discuss their legal rights and options [1][4]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the deadline for applications set for October 10, 2025 [8]. - Faruqi & Faruqi is also seeking information from whistleblowers and former employees regarding SelectQuote's conduct [9].

Core Viewpoint - Semler Scientific, Inc. is facing a securities fraud class action lawsuit due to alleged misleading statements regarding a Department of Justice investigation into the company's reimbursement claims related to the QuantaFlo device [3][5]. Group 1: Company Background and Events - On February 28, 2025, Semler disclosed in its Form 10-K that it received a civil investigative demand from the DOJ in July 2017 concerning its reimbursement claims [3]. - Following unsuccessful settlement discussions with the DOJ in February 2025, Semler's share price fell by approximately 9.39%, from $42.92 to $38.89 [3]. - On April 15, 2025, Semler announced a settlement agreement of $29.75 million to resolve all claims, leading to a further decline in share price by about 9.9%, from $34.40 to $31.00 [4]. Group 2: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Semler securities from March 10, 2021, to April 15, 2025, alleging that the company made false or misleading statements regarding the DOJ investigation [5]. - The lawsuit claims that the company failed to disclose material information about the investigation, which resulted in investor damages when the truth was revealed [5].